| 孙子娟,汪海岩,施慧婕,等.程序性死亡因子受体 -1抑制剂联合化疗和贝伐珠单抗一线治疗 RAS突变 MSS型晚期结直肠癌的疗效观察[J].安徽医药,2024,28(9):1850-1855. |
| 程序性死亡因子受体 -1抑制剂联合化疗和贝伐珠单抗一线治疗 RAS突变 MSS型晚期结直肠癌的疗效观察 |
| Clinical efficacy of PD-1 inhibitor combined with chemotherapy and bevacizumab as first-line treatment for advanced MSS colorectal cancer with RAS mutation |
| |
| DOI：10.3969/j.issn.1009-6469.2024.09.034 |
| 中文关键词: 结直肠肿瘤 微卫星稳定 大鼠肉瘤病毒基因突变 程序性死亡因子受体 -1抑制剂 贝伐珠单抗 卡瑞利珠/信迪利 |
| 英文关键词: Colorectal neoplasms Microsatellite stable RAS gene mutation PD-1 inhibitor Bevacizumab Camrelizumab/sintilimab |
| 基金项目: |
|
| 摘要点击次数: 628 |
| 全文下载次数: 348 |
| 中文摘要: |
| 目的评估程序性死亡因子受体 -1(PD-1)抑制剂联合化疗和贝伐珠单抗一线治疗大鼠肉瘤病毒( RAS)基因突变、微卫星稳定( MSS)型晚期结直肠癌病人的疗效及安全性。方法 2021年 6月至 2022年 6月徐州医科大学附属医院收治的 67例 RAS基因突变 MSS型晚期结直肠癌病人分为两组，观察组( n=32)行 PD-1抑制剂联合化疗和贝伐珠单抗，对照组(n=35)行化疗联合贝伐珠单抗，观察两组的治疗效果及不良反应。结果观察组和对照组的客观缓解率( ORR)分别为 78.1%和 51.4%(P<0.05)，疾病控制率(DCR)分别为 96.9%和 77.1%(P<0.05)；观察组中位无进展生存期( mPFS)较对照组延长，分别为 12.9个月和11.2个月，差异有统计学意义( P<0.05)。观察组的不良反应率高于对照组( 90.6%比 88.6%)，差异无统计学意义( P>0.05)，但均可控制，且未发生致死性事件。结论 PD-1抑制剂联合化疗和贝伐珠单抗一线治疗 RAS基因突变 MSS型晚期结直肠癌初步显示疗效显著，此类病人在常规贝伐珠单抗联合化疗的基础上可以考虑加用 PD-1抑制剂。 |
| 英文摘要: |
| Objective To evaluate the efficacy and safety of programmed death factor receptor-1 (PD-1) inhibitor combined with che- motherapy and bevacizumab in first-line treatment of patients with advanced microsatellite-stable (MSS) colorectal cancer with RAS mutation.Methods A total of 67 patients with advanced MSS colorectal cancer wth RAS mutation admitted to The Affiliated Hospitalof Xuzhou Medical University from June 2021 to June 2022 were assigned into two groups, the observation group (n=32) treated with PD-1 inhibitor combined with chemotherapy and bevacizumab, and the control group (n=35) treated with chemotherapy combined with bevacizumab. The efficacy and adverse reactions of the two groups were observed.Results The objective response rates (ORR) of the observation group and the control group were 78.1% and 51.4%, respectively (P<0.05), and the disease control rates (DCR) were 96.9% and 77.1%, respectively (P<0.05). The median progression free survival (mPFS) of the observation group was longer than that of the con-trol group (12.9 months and 11.2 months, respectively), and the difference was statistically significant (P<0.05). The adverse reaction rate of the observation group was higher than that of the control group (90.6% vs.88.6%; P>0.05), but it could be controlled and no fatal event occurred.Conclusion PD-1 inhibitor combined with chemotherapy and bevacizumab in first-line treatment for advanced MSS colorectal cancer with RAS mutation showed initial significant efficacy, therefore PD-1 inhibitor can be added for such patients on the basis of conventional bevacizumab combined with chemotherapy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
